Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.
Mucopolysaccharidoses (MPS) are severe inherited metabolic disorders from the group of lysosomal storage diseases. They are caused by deficiency in the activity of enzymes involved in the degradation of glycosaminoglycans (GAGs) and resultant accumulation of these compounds in the cells of patients. Although enzyme replacement therapy has become available for some MPS types (MPS I, MPS II and MPS VI), this treatment is not efficient when neurological symptoms occur, especially in MPS III (Sanfilippo disease). Recent studies indicated that substrate reduction therapy (SRT) may be an effective option for the treatment of neurodegenerative lysosomal storage diseases, including MPS III. However, previous attempts to SRT for MPS III focused on the use of non-specific inhibitors of GAG synthesis. Thus, we aimed to use the small interfering RNA (siRNA) procedure to control expression of particular genes, whose products are involved in GAG synthesis. In this report we show that, in MPS IIIA fibroblasts, we were able to reduce mRNA levels of four genes, XYLT1, XYLT2, GALTI and GALTII, whose products are involved in GAG synthesis. This decrease in levels of transcripts corresponded to a decrease in levels of proteins encoded by them. Moreover, efficiency of GAG production in these fibroblasts was considerably reduced after treatment of the cells with siRNA. These results indicate that efficient reduction of GAG synthesis may be achieved by the use of siRNA.
Dziedzic
Dariusz
D
Department of Molecular Biology, University of Gdańsk, Kładki 24, Gdańsk, Poland.
Wegrzyn
Grzegorz
G
Jakóbkiewicz-Banecka
Joanna
J
D000465:Algorithms; D002460:Cell Line; D017931:DNA Primers; D005347:Fibroblasts / Q000473:pathology; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods; D006025:Glycosaminoglycans / Q000096:biosynthesis* / Q000235:genetics*; D006801:Humans; D009084:Mucopolysaccharidosis III / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D010430:Pentosyltransferases / Q000235:genetics; D016133:Polymerase Chain Reaction / Q000379:methods; D034741:RNA, Small Interfering / Q000235:genetics*; D012867:Skin / Q000473:pathology; D014158:Transcription, Genetic; D000097608:UDP Xylose-Protein Xylosyltransferase
D017931:DNA Primers; D006025:Glycosaminoglycans; D010430:Pentosyltransferases; D034741:RNA, Small Interfering; D000097608:UDP Xylose-Protein Xylosyltransferase
Glycoconj J. 2002 May-Jun;19(4-5):347-54
12975615
Dev Biol. 2000 Aug 15;224(2):299-311
10926768
Pediatr Res. 2006 Sep;60(3):309-14
16857766
J Appl Genet. 2007;48(4):383-8
17998597
Nucleic Acids Res. 2008 Jul;36(12):4158-71
18558618
J Biomed Sci. 2009 Mar 02;16:26
19272193
Nature. 1999 Aug 19;400(6746):773-6
10466727
Eur J Hum Genet. 2010 Feb;18(2):194-9
19690583
Glycoconj J. 2002 May-Jun;19(4-5):355-61
12975616
Curr Ther Res Clin Exp. 2008 Apr;69(2):166-79
24692796
Methods. 2001 Dec;25(4):402-8
11846609
IDrugs. 2008 Aug;11(8):572-8
18683092
J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):37-45
17588743
J Biol Chem. 2003 Aug 1;278(31):28363-6
12788935
Mol Genet Metab. 2007 Sep-Oct;92(1-2):115-21
17681480
Biotechniques. 2008 Apr;44(5):613-6
18474035
Biochim Biophys Acta. 2002 Dec 19;1573(3):346-55
12417417
Semin Pediatr Neurol. 2008 Sep;15(3):119-26
18708002
J Cell Sci. 2000 Jan;113 Pt 2:193-205
10633071
J Clin Invest. 2001 Jul;108(2):175-80
11457868
Nat Med. 2003 Mar;9(3):347-51
12579197
Biochim Biophys Acta. 2002 Dec 19;1573(3):319-27
12417414
Biochem Biophys Res Commun. 2003 Dec 26;312(4):1220-5
14652004
J Biol Chem. 2007 May 25;282(21):15578-88
17405882
Eur J Hum Genet. 2006 Jul;14(7):846-52
16670689
Oligonucleotides. 2008 Dec;18(4):345-54
18844576
Development. 2005 Aug;132(16):3777-86
16020517
J Biol Chem. 2001 Sep 21;276(38):35429-34
11457822
J Biol Chem. 2000 Aug 25;275(34):25926-30
10852901
J Clin Invest. 2006 Aug;116(8):2290-6
16878173